Genmab ends work on ADC from $1.8B acquisition of ProfoundBio

Genmab has stopped development of an early-stage antibody-drug conjugate that it swooped up in its $1.8 billion acquisition of ProfoundBio last year. The Danish biopharma ended clinical development of GEN1107, or PRO1107 ...